Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Pain 20Neoplasms 19Cancer Pain 16Pain, Postoperative 12Agnosia 8Chronic Pain 7Breast Neoplasms 5Neoplasm Metastasis 4Head and Neck Neoplasms 4Colorectal Neoplasms 4Colonic Neoplasms 4Multiple Myeloma 3Mucositis 3Lymphoma, Follicular 3Lymphoma 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Leukemia, Biphenotypic, Acute 3Leukemia 3Wounds and Injuries 2Waldenstrom Macroglobulinemia 2Thrombocythemia, Essential 2Supratentorial Neoplasms 2Sezary Syndrome 2Primary Myelofibrosis 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Precancerous Conditions 2Polycythemia Vera 2Pdgfra-Associated Chronic Eosinophilic Leukemia 2

Interventions

salicylhydroxamic acid 1nilotinib 1morphine, naltrexone combination 1Naltrexone 1Morphine 1Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Substance Withdrawal Syndrome × Morphine × Clear all
NCT01100437 2012-07-13

Safety Study to Assess Opiate Withdrawal Signs and Symptoms in Opioid Dependent Patients

Pfizer

Phase 4 Terminated
14 enrolled 18 charts

Substance Withdrawal Syndrome, Chronic Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡